Literature DB >> 32076874

Incidence and risk of antiresorptive agent-related osteonecrosis of the jaw (ARONJ) after tooth extraction in patients with autoimmune disease.

Yuichiro Fujieda1, Mototsugu Doi2, Takuya Asaka3, Masahiro Ota4, Ryo Hisada2, Naoki Ohnishi2, Michihiro Kono2, Hiraku Kameda2, Daigo Nakazawa2, Masaru Kato2, Olga Amengual2, Masahiko Takahata4, Shinsuke Yasuda2, Yoshimasa Kitagawa3, Tatsuya Atsumi2.   

Abstract

INTRODUCTION: Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) is a rare but serious complication in patients receiving antiresorprtive agents (AR). However, the incidence of ARONJ after tooth extraction in patients with autoimmune disease (AID) remains unclear. The present study aimed to clarify the high-risk population of ARONJ in patients with AID.
MATERIALS AND METHODS: The study population comprised 232 patients treated with AR, AID or non-AID, who had undergone dental extraction from January 2011 to September 2017. The incidence and risk factors of ARONJ were analysed retrospectively. Additionally, the relationship between ARONJ and osteoporotic fracture (OF) and AR discontinuation during dental procedures was investigated.
RESULTS: Of 232 patients, 10 developed ARONJ within 1 year of dental extraction. The incidence of ARONJ in patients with AID was higher than that in non-AID patients (2.0/100 person-year vs 0.5/100 person-year; p = 0.03). Among the AID patients, RA patients had strikingly high incidence of ARONJ (3.6/100 person-year). The incidence of neither ARONJ nor OF significantly differed between patients who continued and discontinued AR in the perioperative period.
CONCLUSION: Patients with AID who undergo dental extraction are at high risk of ARONJ. Discontinuation of AR would not significantly contribute to reduce the incidence of ARONJ in those patients.

Entities:  

Keywords:  Antiresorptive agents-related osteonecrosis of the jaw; Autoimmune disease; Osteoporosis; Rheumatoid arthritis

Mesh:

Substances:

Year:  2020        PMID: 32076874     DOI: 10.1007/s00774-020-01089-y

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  24 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report.

Authors:  Tuhina Neogi; Daniel Aletaha; Alan J Silman; Raymond L Naden; David T Felson; Rohit Aggarwal; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Dinesh Khanna; Tore K Kvien; Timothy Laing; Katherine Liao; Philip Mease; Henri A Ménard; Larry W Moreland; Raj Nair; Theodore Pincus; Sarah Ringold; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovský; Frederick Wolfe; Gillian Hawker
Journal:  Arthritis Rheum       Date:  2010-09

3.  Revised Japanese criteria for Sjögren's syndrome (1999): availability and validity.

Authors:  Takashi Fujibayashi; Susumu Sugai; Nobuyuki Miyasaka; Yoshio Hayashi; Kazuo Tsubota
Journal:  Mod Rheumatol       Date:  2004-12       Impact factor: 3.023

4.  2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.

Authors:  Frank van den Hoogen; Dinesh Khanna; Jaap Fransen; Sindhu R Johnson; Murray Baron; Alan Tyndall; Marco Matucci-Cerinic; Raymond P Naden; Thomas A Medsger; Patricia E Carreira; Gabriela Riemekasten; Philip J Clements; Christopher P Denton; Oliver Distler; Yannick Allanore; Daniel E Furst; Armando Gabrielli; Maureen D Mayes; Jacob M van Laar; James R Seibold; Laszlo Czirjak; Virginia D Steen; Murat Inanc; Otylia Kowal-Bielecka; Ulf Müller-Ladner; Gabriele Valentini; Douglas J Veale; Madelon C Vonk; Ulrich A Walker; Lorinda Chung; David H Collier; Mary Ellen Csuka; Barri J Fessler; Serena Guiducci; Ariane Herrick; Vivien M Hsu; Sergio Jimenez; Bashar Kahaleh; Peter A Merkel; Stanislav Sierakowski; Richard M Silver; Robert W Simms; John Varga; Janet E Pope
Journal:  Arthritis Rheum       Date:  2013-10-03

5.  The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis.

Authors:  W P Arend; B A Michel; D A Bloch; G G Hunder; L H Calabrese; S M Edworthy; A S Fauci; R Y Leavitt; J T Lie; R W Lightfoot
Journal:  Arthritis Rheum       Date:  1990-08

6.  Evaluation of peri-implant bone metabolism under immediate loading using high-resolution Na18F-PET.

Authors:  Yutaka Matsuo; Toru Ogawa; Miou Yamamoto; Aya Shibamoto; Juan Ramón Vanegas Sáenz; Masayoshi Yokoyama; Yoshiaki Kanda; Jun Toyohara; Keiichi Sasaki
Journal:  Clin Oral Investig       Date:  2016-11-12       Impact factor: 3.573

7.  Impact of Osteonecrosis of the Jaw on Osteoporosis Treatment in Japan: Results of a Questionnaire-Based Survey by the Adequate Treatment of Osteoporosis (A-TOP) Research Group.

Authors:  Akira Taguchi; Masataka Shiraki; Mayumi Tsukiyama; Teruhiko Miyazaki; Satoshi Soen; Hiroaki Ohta; Toshitaka Nakamura; Hajime Orimo
Journal:  Calcif Tissue Int       Date:  2015-07-26       Impact factor: 4.333

8.  Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday.

Authors:  J R Curtis; A O Westfall; H Cheng; E Delzell; K G Saag
Journal:  Osteoporos Int       Date:  2008-05-16       Impact factor: 4.507

Review 9.  RANKL: A therapeutic target for bone destruction in rheumatoid arthritis.

Authors:  Sakae Tanaka; Yoshiya Tanaka; Naoki Ishiguro; Hisashi Yamanaka; Tsutomu Takeuchi
Journal:  Mod Rheumatol       Date:  2017-09-18       Impact factor: 3.023

10.  Lack of cooperation between physicians and dentists during osteoporosis treatment may increase fractures and osteonecrosis of the jaw.

Authors:  Akira Taguchi; Masataka Shiraki; Toshitsugu Sugimoto; Hiroaki Ohta; Satoshi Soen
Journal:  Curr Med Res Opin       Date:  2016-04-19       Impact factor: 2.580

View more
  3 in total

Review 1.  Medication-Related Osteonecrosis of the Jaw (MRONJ): Are Antiresorptive Drugs the Main Culprits or Only Accomplices? The Triggering Role of Vitamin D Deficiency.

Authors:  Luca Dalle Carbonare; Monica Mottes; Maria Teresa Valenti
Journal:  Nutrients       Date:  2021-02-08       Impact factor: 5.717

2.  Mechanism of bisphosphonate-related osteonecrosis of the jaw (BRONJ) revealed by targeted removal of legacy bisphosphonate from jawbone using competing inert hydroxymethylene diphosphonate.

Authors:  Hiroko Okawa; Takeru Kondo; Akishige Hokugo; Philip Cherian; Jesus J Campagna; Nicholas A Lentini; Eric C Sung; Samantha Chiang; Yi-Ling Lin; Frank H Ebetino; Varghese John; Shuting Sun; Charles E McKenna; Ichiro Nishimura
Journal:  Elife       Date:  2022-08-26       Impact factor: 8.713

Review 3.  The role of antiresorptive drugs and medication-related osteonecrosis of the jaw in nononcologic immunosuppressed patients: A systematic review.

Authors:  Roberto Sacco; Julian Woolley; Julian Yates; Monica Diuana Calasans-Maia; Oladapo Akintola; Vinod Patel
Journal:  J Res Med Sci       Date:  2021-03-31       Impact factor: 1.852

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.